Michael A. Willen

Statistics

Publications

Citations

315

H-Index

Active since

2006

Affiliations

Hematology Oncology Associates(Current)

Michael A. Willen is an author at Hematology Oncology Associates specializing in bortezomib-based therapy, medicine, and hematologic malignancy therapy.

Publications per year

2006–2011

Publications

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai et al. · Journal of Clinical Oncology · 2009 · 290 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Steven P. Treon, Jacob D. Soumerai, Christopher J. Patterson et al. · Blood · 2006 · 15 citations

Medicine, Hematology, Pharmacotherapy +13

Creating a Process to Standardize Regimen Order Sets Within an Electronic Health Record

Leslie T. Busby, Sheetal Sheth, Jody S. Garey et al. · Journal of Oncology Practice · 2011 · 10 citations · Full text

Pharmacy, Clinical Pharmacy, Oncology +15

1–3 of 3